DKN-01 and tislelizumab plus chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

被引：0
|
作者：
Klempner, S. J. [1 ]
Chao, J. [2 ]
Uronis, H. [3 ]
Sirard, C. [4 ]
Kagey, M. [5 ]
Baum, J. [5 ]
Song, J. [6 ]
Wang, J. [7 ]
Sonbol, M. B. [8 ]
Wainberg, Z. A. [9 ]
Ajani, J. A. [10 ]
机构：
[1] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA
[3] Duke Univ, Med, Duke Canc Ctr, Med Ctr, Durham, NC USA
[4] Leap Therapeut, Clin Dev, Cambridge, MA USA
[5] Leap Therapeut, Translat Med, Cambridge, MA USA
[6] BeiGene Ltd, Biostat, San Mateo, CA USA
[7] BeiGene Ltd, Clin Dev, Beijing, Peoples R China
[8] Mayo Clin, Internal Med Dept, Canc Ctr, Phoenix, AZ USA
[9] UCLA, Med Hematol & Oncol, David Geffen Sch Med, Los Angeles, CA USA
[10] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1213P
引用
收藏
页码：S1103 / S1104
页数：2
相关论文
共 50 条
  • [41] Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.
    Li, Yi
    Zhao, Chuanhua
    Liu, Rongrui
    Xu, Sheng
    Miao, Xiaojie
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 413 - 413
  • [42] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Shi, Xuan-Qiong
    Li, Qiu
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [43] Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).
    Park, Wungki
    Wong, Winston
    Yu, Kenneth H.
    Varghese, Anna M.
    Riaz, Nadeem
    Balachandran, Vinod P.
    El Dika, Imane H.
    Raj, Nitya Prabhakar
    Khalil, Danny
    Ku, Geoffrey Yuyat
    Segal, Neil Howard
    Li, Jia
    Chalasani, Sree Bhavani
    Chong, Curtis Robert
    Kelsen, David Paul
    Abou-Alfa, Ghassan K.
    Berger, Michael F.
    Schultz, Nikolaus
    Iacobuzio-Donahue, Christine A.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
    Sugarman, Ryan
    Nunna, Sasikiran
    Betts, Keith A.
    Nie, Xiaoyu
    Nguyen, Hiep
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
    Kato, K.
    Yoon, H.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Park, S. R.
    Ping, L.
    Jiang, Y.
    Zhang, J.
    Wu, X.
    Yao, Y.
    Shen, L.
    Kojima, T.
    Lin, C-Y.
    Wang, L.
    Tao, A.
    Peng, Y.
    Li, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1458 - S1458
  • [46] A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).
    Eads, Jennifer Rachel
    Stein, Stacey
    El-Khoueiry, Anthony B.
    Manji, Gulam Abbas
    Abrams, Thomas Adam
    Khorana, Alok A.
    Miksad, Rebecca A.
    Mahalingam, Devalingam
    Sirard, Cynthia A.
    Zhu, Andrew X.
    Goyal, Lipika
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Bragagnoli, Campos A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Li, M.
    Cullen, D.
    Memaj, A.
    Lei, M.
    Xiao, H.
    Janjigian, Y. Y.
    Ajani, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 79 - 80
  • [48] TREATMENT OF ADVANCED BILIARY TRACT CANCER (BTC) AFTER PROGRESSION ON FIRST-LINE (1L) SYSTEMIC THERAPY
    Danese, M.
    Lubeck, D.
    Gleeson, M.
    Bobiak, S.
    VALUE IN HEALTH, 2019, 22 : S498 - S499
  • [49] Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)
    Obarevich, E.
    Besova, N.
    Trusilova, E.
    Gorbunova, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
    Shen, Lin
    Zhang, Yanqiao
    Li, Ziyu
    Zhang, Xiaotian
    Gao, Xiangyu
    Liu, Bo
    Wang, Yusheng
    Ba, Yi
    Li, Ning
    Zhang, Ruixing
    Zhang, Jingdong
    Chen, Ye
    Chen, Jian
    Huang, Mingzhu
    Fu, Yang
    Liu, Mulin
    Liu, Zheng
    Zhao, Jun
    Li, Wei
    Wei, Jia
    Li, Changzheng
    Xu, Nong
    Guo, Zengqing
    Cao, Bangwei
    Liu, Lian
    Nie, Peng
    Wan, Lixin
    Sheng, Lili
    Liu, Zhenyang
    He, Yifu
    Gu, Kangsheng
    Wu, Guowu
    Wang, Weibo
    Zhang, Futong
    Qiu, Wensheng
    Guo, Jun
    Ying, Jieer
    Pan, Hongming
    Xu, Huiting
    Yuan, Yuan
    Bai, Yuansong
    Wang, Zhenghua
    Xu, Jiye
    Zhao, Xuehong
    Liu, Hao
    Zhang, Xizhi
    Dai, Wenxiang
    Xu, Hongyan
    Liu, Ming
    Xie, Lin
    NATURE MEDICINE, 2025, : 1163 - 1170
12345